(R)-(-)-Ibuprofen

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

布洛芬的一种对映体，通常不被认为是 COX 抑制剂，而是被认为参与脂质代谢途径，因为它与脂肪酸一起掺入甘油三酯中。

An enantiomer of Ibuprofen that is generally not considered a COX inhibitor and is instead thought to be involved in pathways of lipid metabolism as it is incorporated into triglycerides along with fatty acids; inhibits NF-κB activation (IC50=121.8 uM) in response to T-cell stimulation as well as block superoxide formation, β-glucuronidase release, and LTB4 generation by stimulated neutrophils (IC50 =40-100 uM).Pain Approved.

(R)-(-)-Ibuprofen is the R enantiomer of Ibuprofen, with no inhibitory effect on COX, but is involved in pathways of lipid metabolism and is incorporated into triglycerides along with endogenous fatty acids. (R)-(-)-Ibuprofen (1 μM) significantly reduces NF-κB activation and completely prevents NF-κB induction at 10 μM. (R)-(-)-Ibuprofen inhibits NF-κB luciferase activity with an IC50 of 121.8 μM, weaker than that of S(+)-ibuprofen (IC50, 61.7 μM). Furthermore, (R)-(-)-Ibuprofen (10 mM) has no effect on HSF.

——

R)-Ibuprofen

Apoptosis

NF-κB

NF-κB

Neurological Disease

Pain

51146-57-7

206.2808

C13H18O2

>98% (HPLC)

10 mM in DMSO

O=C(O)[C@H](C)C1=CC=C(CC(C)C)C=C1

Benzeneacetic acid, α-methyl-4-(2-methylpropyl)-,(αR)-

(-20℃)

With Ice Pack

≥ 2 years